Non-Small Cell Lung Cancer
Conditions
Keywords
Tumour Volume, Prognostic value
Brief summary
The main aim is to determine, in patients with locoregional, non-small cell lung cancer (NSCLC) treated by definitive radiotherapy, the influence on survival of the volume of primary tumour, as measured from CT imaging, after adjusting for the effect of the current TNM staging system and other known prognostic factors (especially ECOG performance and weight loss).
Detailed description
Patients with locoregional non small cell lung cancer are registered on study after tumour volumes are outlined by a radiologist and prior to the commencement of any treatment. All patients must have recorded the volume of disease in the primary tumour (and of involved nodes \> 1 cm diameter) as measured from a CT scan performed according to a standard set of conditions. Following registration patients are treated with Definitive radiotherapy with or without chemotherapy. Follow-up will occur with the collection of a minimum amount of data every 12 months from the date of registration on study. Quality Assurance procedures will be implemented with each site that participates in the study.
Interventions
RADIATIONDefinitive Radiotherapy
60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
Sponsors
Peter MacCallum Cancer Centre, Australia
Trans Tasman Radiation Oncology Group
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Must satisfy ALL of the following * NSCLC - histological or cytological diagnosis of non-small cell lung cancer * Intra-thoracic disease - disease is confined to the primary site, with or without intrathoracic lymph nodes * CT planning - CT imaging of the thorax has been performed as part of the planning procedure * Definitive radiotherapy - it is planned to give definitive radiotherapy with or without chemotherapy (prior to, during or after radiotherapy). Definitive radiotherapy is defined as 60 Gy in 6 weeks, 50 Gy in 4 weeks or at least the equivalent of either of these. The size of each individual; fraction should not exceed 2.5 Gy. * Measurable disease - the primary tumour and nodes with maximum diameter greater than 1cm represent measurable disease
Exclusion criteria
A patient satisfying ANY of the following is ineligible * Symptomatic or radiological evidence of metastatic disease * Prior treatment for non-small cell lung cancer * Surgical resection is part of initial treatment * Palliative radiotherapy planned
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival | End of Study | Survival duration defined as the time from date of registration until death from any cause |
Countries
Australia, New Zealand, Singapore
Outcome results
None listed